Is 9OF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9OF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9OF's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9OF's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9OF?
Key metric: As 9OF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 9OF. This is calculated by dividing 9OF's market cap by their current
revenue.
What is 9OF's PS Ratio?
PS Ratio
27.3x
Sales
US$377.00k
Market Cap
US$10.31m
9OF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 9OF is expensive based on its Price-To-Sales Ratio (27.3x) compared to the European Biotechs industry average (8.1x).
Price to Sales Ratio vs Fair Ratio
What is 9OF's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
9OF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
27.3x
Fair PS Ratio
26.8x
Price-To-Sales vs Fair Ratio: 9OF is expensive based on its Price-To-Sales Ratio (27.3x) compared to the estimated Fair Price-To-Sales Ratio (26.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 9OF forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€1.33
€12.35
+828.5%
38.5%
€17.10
€7.60
n/a
2
Dec ’25
€1.33
€12.35
+828.5%
38.5%
€17.10
€7.60
n/a
2
Nov ’25
€1.36
€10.89
+701.0%
50.0%
€16.34
€5.45
n/a
2
Oct ’25
€1.44
€10.89
+656.5%
50.0%
€16.34
€5.45
n/a
2
Sep ’25
€1.35
€10.89
+706.9%
50.0%
€16.34
€5.45
n/a
2
Aug ’25
€1.30
€9.81
+654.7%
42.9%
€14.02
€5.61
n/a
2
Jul ’25
€1.77
€9.81
+454.3%
42.9%
€14.02
€5.61
n/a
2
Jun ’25
€0.97
€9.77
+907.5%
42.9%
€13.96
€5.58
n/a
2
May ’25
€1.35
€9.82
+627.5%
42.9%
€14.03
€5.61
n/a
2
Apr ’25
€1.26
€11.64
+823.6%
20.0%
€13.97
€9.31
n/a
2
Mar ’25
€1.42
€11.60
+717.1%
20.0%
€13.92
€9.28
n/a
2
Dec ’24
€1.74
€11.45
+558.2%
20.0%
€13.74
€9.16
€1.33
2
Nov ’24
€1.84
€11.45
+522.4%
20.0%
€13.74
€9.16
€1.36
2
Oct ’24
€1.47
€11.45
+679.1%
20.0%
€13.74
€9.16
€1.44
2
Sep ’24
€1.99
€11.45
+475.5%
20.0%
€13.74
€9.16
€1.35
2
Aug ’24
€2.58
€11.45
+343.9%
20.0%
€13.74
€9.16
€1.30
2
Jul ’24
€3.86
€11.45
+196.7%
20.0%
€13.74
€9.16
€1.77
2
Jun ’24
€4.78
€9.54
+99.7%
42.9%
€13.63
€5.45
€0.97
2
May ’24
€3.66
€9.51
+159.8%
42.9%
€13.58
€5.43
€1.35
2
Apr ’24
€3.22
€9.93
+208.3%
42.9%
€14.18
€5.67
€1.26
2
Mar ’24
€2.56
€9.99
+290.2%
42.9%
€14.27
€5.71
€1.42
2
Feb ’24
€2.66
€9.99
+275.6%
42.9%
€14.27
€5.71
€1.56
2
Jan ’24
€2.44
€9.99
+309.4%
42.9%
€14.27
€5.71
€1.60
2
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.